- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$58.50 BnMarket Estimate, 2026
$63.64 BnMarket Forecast, 2034
$124.87 BnCAGR, 2026–2034
8.79%Executive Summary: Middle East and Africa Protein A Resins Market
- Market Scope: Regional analysis of the Middle East and Africa's protein a resins sector, detailing product types, applications, matrix types, end users, and country-level profiles.
- Market Valuation: Valued at USD 58.50 billion in 2025, reaching USD 63.64 billion in 2026, and projected to expand to USD 124.87 billion by 2034, growing at a robust CAGR of 8.79% from 2026 to 2034.
- Primary Growth Drivers: Growing demand for biosimilars and biologics, increasing R&D investments in proteomics, rising prevalence of chronic diseases such as cancer, and favorable government healthcare initiatives.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Product Type | Recombinant Protein A Resin (dominated base year due to high purity, consistency, and widespread use in bioprocessing) | Recombinant Protein A Resin (projected at a higher growth rate driven by advanced genetic engineering and scale-up efficiency) |
| By Application | Antibody Purification (captured major market share supported by extensive monoclonal antibody production pipelines) | Immunoprecipitation (growing rapidly due to increased proteomics research and target protein analysis) |
| By Matrix Type | Agarose (held dominant share owing to high chemical stability, excellent flow properties, and standard industry adoption) | Organic Polymer (fastest-growing matrix type driven by superior mechanical strength and high-pressure processing compatibility) |
| By End User | Biopharmaceutical Manufacturers (dominated base year backed by large-scale commercial therapeutic production) | Clinical Research Laboratories (fastest-growing segment propelled by rising biomarker discovery and early-stage drug development) |
| By Country | Saudi Arabia (market leader in the Middle East region, backed by heavy investments in healthcare infrastructure and biopharma R&D) | Egypt (fastest-growing regional hub with a 7.5% CAGR, driven by rising local manufacturing investments and biopharmaceutical expansions) |
Major Market Players & Industry Landscape
Market Structure: Consolidated industrial landscape featuring global biotechnology and life sciences corporations partnering with local research networks to advance biopharmaceutical manufacturing capabilities across the MEA region.
Key Companies: GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific, EMD Millipore, and Expedeon Ltd.
Download Free Sample Report
Middle East and Africa Protein A Resins Market Size
The Middle East & Africa Protein A Resins Market was valued at USD 58.50 billion in 2025, is estimated to reach USD 63.64 billion in 2026, and is projected to reach USD 124.87 billion by 2034, growing at a CAGR of 8.79% from 2026 to 2034.
Protein A resin is based on affinity chromatography, and they are used as an easy one-step purification of immunoglobulins from biological fluids and cell culture media. In addition, these resins also find their use in immunoprecipitation of proteins, protein complexes or antigens, monoclonal antibodies, etc. Factors such as growing demand for biosimilars/biologics and increasing investment in research and biosimilars/proteomics are the significant drivers of the protein a resins market in this region. For instance, the protein A resin can cause inflammation in the lung tissue by binding to the tumor necrosis factor 1(TNFR-1) receptors. This interaction has been shown to detect the pathogenesis of pneumonia caused by staphylococci.
They can be used to study drugs, toxins, or radioactive substances directly to cancer cells and treat chronic diseases such as cancer and rheumatoid arthritis. The market shows clear potential during the forecast period owing to the increase in research and development supported by favorable government initiatives, which are estimated to drive the sales of Protein A. In addition, an increased prevalence of serious diseases such as cancer has led to investments in research and development to develop effective drugs, leading to an increase in the market demand for protein A resins. The rate of cancer is increasing by 1 to 1.30 % every year across the globe. In 2019, Pneumonia had caused over 14% of total deaths of children under the age of 5, accounting for 740,200 deaths. Although pneumonia affects children and families across the globe, however, the highest number of deaths have been recorded in South Asia and sub-Saharan Africa. In addition, the growing need for early diagnosis of the diseases, coupled with the increasing emphasis on good quality healthcare, will pave the way for growth opportunities during the forecast period.
The high cost of protein A resins coupled with growing awareness of alternative methods to purify monoclonal antibodies such as crystallization, ultrafiltration, capillary electrophoresis, and high-pressure folding are expected to slow down the growth rate of the MEA protein A resin market.
Geographically, the Middle East is projected to dominate the MEA protein A resin market during the forecast period, owing to the increasing demand for the pharmaceuticals and biopharmaceuticals sector in the region.
Saudi Arabia is anticipated to register a 7.5% CAGR between 2026 to 2034 due to the increasing demand for therapeutic antibodies, and extensive research on monoclonal antibodies will drive the market. In addition, the growing prevalence of cancer has encouraged the government and pharmaceutical companies to invest in the studied market to increase the market revenue. This pharmaceutical market had sales and R&D over a value of approximately $ 235 million in 2018.
The Egypt protein A resin sales are expected to increase at an impressive 7.5% CAGR during the forecast period, owing to the region's high investment in biopharmaceutical companies. In 2018, Pharmaceuticals preparations, manufacturing, operating had seen a grand profit of approximately US $ 925 million.
The African region is expected to account for almost 15% of the share in MEA due to the growing number of biopharmaceutical companies focusing on the development of biosimilar drugs. In South Africa, the biopharmaceutical market reached approximately USD 3.6 billion in growing sales in 2018.
KEY MARKET PLAYERS
A few notable companies operating in the MEA Protein A Resins Market profiled in the report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific EMD Millipore, and Expedeon Ltd.
MARKET SEGMENTATION
This research report on the Middle East and Africa Protein A Resins market has been segmented and sub-segmented into the following categories:
By Product Type
- Natural Protein A Resin
- Recombinant Protein A Resin
By Application
- Immunoprecipitation
- Antibody Purification
By Matrix Type
- Glass or Silica
- Agarose
- Organic Polymer
By End Users
- Biopharmaceutical Manufacturers
- Clinical Research Laboratories
- Academic Institutions
By Country
- KSA
- UAE
- Israel
- rest of GCC countries
- South Africa
- Ethiopia
- Kenya
- Egypt
- Sudan
- rest of MEA